-

ArteraAI and GenesisCare Partner to Launch the First Australian-Based Clinical Trial

SAN FRANCISCO & SYDNEY--(BUSINESS WIRE)--ArteraAI, the developer of multimodal artificial intelligence (MMAI) based predictive and prognostic cancer tools, today announced a strategic collaborative agreement with GenesisCare, an integrated cancer care provider.

The agreement allows for ArteraAI and GenesisCare to collaborate in Australia to generate real-world data on AI tools guiding treatment decisions as part of a new clinical trial.

“We are honored to be able to partner with GenesisCare to provide the clinical community in Australia a way to personalize care for their patients,” said Andre Esteva, co-founder and CEO of ArteraAI.

ArteraAI and GenesisCare share a commitment to clinical innovation and advancing precision medicine, with the aim of improving the lives of patients with localized prostate cancer.

“Our research partnership with ArteraAI aligns with our aim to offer personalized and patient-centric care in communities across Australia,” said Professor Jarad Martin, GenesisCare Radiation Oncologist.

About ArteraAI

ArteraAI is a leading precision medicine company developing AI tools to personalize cancer therapy.

ArteraAI’s multimodal artificial intelligence (MMAI) biomarker tool leverages a unique algorithm that assesses digital images from a patient’s biopsy and learns from a patient's clinical data. The AI combines this information to predict whether a patient will benefit from a particular therapy and determine their prognosis.

About GenesisCare Australia

GenesisCare is an integrated cancer care provider that aims to change the face of cancer care with modern treatments and techniques designed to achieve the best possible life outcomes for patients. In Australia, GenesisCare provides care to approximately 30,000 patients a year across 48 locations in metro and regional Victoria, New South Wales, Queensland, South Australia, and Western Australia. GenesisCare’s vision is to offer patients personalized, high-quality care throughout their cancer journey. For more information, visit www.genesiscare.com.

Contacts

Media:
Lesley Swiger
Antenna
artera@antennagroup.com
(202) 869-1612

Industry:

ArteraAI

Release Versions
English

Contacts

Media:
Lesley Swiger
Antenna
artera@antennagroup.com
(202) 869-1612

More News From ArteraAI

Artera Receives U.S. FDA Clearance for ArteraAI Breast, Expanding Its AI Platform to Breast Cancer

SAN FRANCISCO--(BUSINESS WIRE)--Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, today announced U.S. Food and Drug Administration (FDA) clearance of ArteraAI Breast for use in patients with early-stage, hormone receptor-positive (HR+), HER2-negative invasive breast cancer. ArteraAI Breast is the first and only FDA-cleared digital pathology-based risk stratification tool for breast cancer. With clearances in both prostate and breas...

Artera Secures CE Marking for Its AI Prostate and Breast Cancer Assays, Unlocking Global Expansion

SAN FRANCISCO--(BUSINESS WIRE)--Artera, a developer of multimodal AI-based prognostic and predictive cancer tests, announced today that it was granted CE marking under the European Union In Vitro Diagnostic Regulation (EU IVDR) for both its ArteraAI Prostate Biopsy Assay and ArteraAI Breast Cancer Assay, marking a major step in the company’s global expansion. The ArteraAI Prostate Biopsy Assay is the first CE-marked AI-enabled prognostic and predictive in vitro diagnostic (IVD) test for prostat...

Artera Debuts ArteraAI Prostate Test (Post‑RP), Expanding its Oncology Portfolio

SAN FRANCISCO--(BUSINESS WIRE)--Artera, a developer of multimodal AI-based prognostic and predictive cancer tests, today announced the commercial launch of the ArteraAI Prostate Test (Post‑RP) for patients experiencing biochemical recurrence (BCR) following radical prostatectomy. The test builds on the established ArteraAI platform and delivers prognostic results and insights into short-term ADT benefit to optimize decision-making in the salvage therapy setting, where additional treatment is gi...
Back to Newsroom